Management of Co‑occurring Depression and Anxiety

Epidemiology & Clinical Significance

• Approximately 50–60 % of individuals diagnosed with a depressive disorder also meet criteria for a comorbid anxiety disorder, most often generalized anxiety disorder. 1
• In patients with major depressive disorder, ≈ 56 % have a concurrent anxiety disorder. 3

Screening Recommendations

General Screening Strategy

• Simultaneous screening for depression and anxiety with validated instruments is recommended in primary‑care settings. 5
• Annual screening during preventive health visits is advised, with more frequent assessment for high‑risk groups (e.g., chronic medical illness, substance use, family history, prior episodes). [5][7]

Population‑Specific Guidance

• Women and adolescent girls ≥ 13 years should be screened for anxiety. 6
• All adults should be screened for depression. 7

Recommended Instruments

• Combined tools (e.g., PHQ‑4, HADS, Edinburgh Postnatal Depression Scale) improve efficiency. 5
• Depression: PHQ‑9 ≥ 10 indicates moderate depression; HADS‑D ≥ 8 indicates caseness; HAM‑D scores 7‑17 mild, 18‑24 moderate, ≥ 25 severe. [1][8]
• Anxiety: HADS‑A ≥ 8 indicates caseness; Penn State Worry Questionnaire assesses generalized anxiety; STAI is also used. [1][8]

Screening Frequency

• Optimal interval is unknown; clinicians should use judgment. 5

Treatment Approach

Initial Prioritisation

• When both conditions are present, treat depression first unless anxiety is more severe or functionally disabling. 1

Step 1 – Exclude Medical Contributors

• Rule out pain, fatigue, delirium, infection, electrolyte or thyroid abnormalities, and substance‑induced symptoms before psychiatric treatment. [2][9]

Step 2 – Severity & Risk Assessment

• Immediate psychiatric referral is required for self‑harm risk, risk to others, or psychotic features. [2][9]
• Identify the primary disorder based on severity, functional impact, temporal pattern, and patient‑reported burden. 1

Step 3 – First‑Line Interventions

Moderate‑to‑Severe Depression with Comorbid Anxiety

• Cognitive‑behavioral therapy (CBT) is the preferred psychotherapy. 3
• SSRIs or SNRIs (e.g., sertraline, paroxetine, fluoxetine, venlafaxine, duloxetine) are first‑line pharmacologic agents. 3

Mild‑to‑Moderate Symptoms

• Psychotherapy alone (CBT, psycho‑educational therapy, behavioral activation, interpersonal therapy) may suffice. 2
• Exercise can be used as an adjunctive treatment. 2

Medication Selection Considerations

• Choose agents based on adverse‑effect profile, drug‑drug interactions, prior response, patient preference, and specific clinical scenarios. [2][9]

Special Populations

• Ages 18‑29: Prefer psychotherapy first or non‑SSRI agents due to heightened suicidal risk with SSRIs. 7
• Ages ≥ 65: Prefer psychotherapy first or non‑SSRI agents because SSRIs increase gastrointestinal bleeding risk. 7
• Concurrent NSAID/aspirin use raises GI bleeding risk when combined with SSRIs. 7

Benzodiazepine Use

• Limit benzodiazepines to short‑term “bridging” for acute anxiety; avoid long‑term use because of abuse potential, dependence, and cognitive impairment. [9][10]

Monitoring & Follow‑Up

• Biweekly to monthly monitoring until symptom remission is achieved. 2
• Assess treatment adherence, patient satisfaction, adverse effects, and functional improvement at each visit. [2][9]
• If no improvement after 8 weeks, modify the treatment plan (change medication, add psychotherapy, or refer to specialty care). 2

Common Clinical Pitfalls

• Treating anxiety without addressing co‑existent depression often leads to suboptimal outcomes; depression should be targeted first. 1
• Prolonged benzodiazepine therapy is discouraged, especially in patients with a history of substance misuse. 9
• Failing to screen for both disorders results in incomplete treatment and poorer clinical outcomes. 5